Immix Biopharma, Inc.
IMMX
$1.99
-$0.42-17.43%
NASDAQ
| 03/31/2025 | 12/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | -25.05% | 22.49% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -6.10% | -32.56% | |||
| Operating Income | 6.10% | 32.56% | |||
| Income Before Tax | 5.59% | 32.74% | |||
| Income Tax Expenses | -9.26% | -2.70% | |||
| Earnings from Continuing Operations | 5.60% | 32.69% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 5.60% | 32.69% | |||
| EBIT | 6.10% | 32.56% | |||
| EBITDA | 6.48% | 32.79% | |||
| EPS Basic | 6.08% | 33.00% | |||
| Normalized Basic EPS | 6.01% | 33.05% | |||
| EPS Diluted | 6.08% | 33.00% | |||
| Normalized Diluted EPS | 6.01% | 33.05% | |||
| Average Basic Shares Outstanding | 0.46% | 0.47% | |||
| Average Diluted Shares Outstanding | 0.46% | 0.47% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||